Remove 2020 Remove Compounding Remove Pharmaceutical Companies
article thumbnail

The digital transformation of pharma’s physician engagement strategies

pharmaphorum

The pandemic has ushered in a number of major changes to healthcare systems, notably in the ways in which pharmaceutical companies communicate, visit and engage with physicians. The threat of disease spread and other risk factors from COVID-19 have only compounded this. How engagement with HCPs will evolve in the future.

article thumbnail

Clinical success begins early for small molecule drugs

European Pharmaceutical Review

Ensuring that small and emerging pharmaceutical companies have access to expertise and resources is especially important. 2 However, smaller companies may have limited in-house resources and lack the capabilities to solve the challenges to meet important milestones during early-stage development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Utilising content metrics to improve digital engagement

pharmaphorum

The report refers to data collected across 350+ global pharma companies between November 2020 through January 2021, and notes a 70% compound average growth rate in the volume of content managed in Veeva Vault PromoMats since 2018. Veeva is the global leader in cloud software for the life sciences industry.

article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Large CMOs held the biggest share of revenue in 2021, as even from the initial stages of drug production, pharmaceutical firms decided to outsource the work to these organisations.

Dosage 98
article thumbnail

Adapting Customer Engagement Strategies to the COVID Landscape

Pharma Marketing Network

In office/in person sales promotion, the staple of pharmaceutical company activities, is simply not possible today with interactions reduced to the sporadic video or to telephone engagement. This will result in permanent shifts in how HCPs and patients interact with pharmaceutical companies.

article thumbnail

Formulation development outsourcing market to be worth over $60bn by 2030

European Pharmaceutical Review

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 Pharmaceutical companies globally are significantly investing in R&D. For instance, in 2020, Merck’s R&D cost was approximately $2.5 percent from its 2022 value of $35.1 billion and Biogen’s approximately $4 billion.

article thumbnail

The role of outsourcing in antibody drug manufacture

European Pharmaceutical Review

A study investigating the trend for existing pharmaceutical companies to outsource to contracted development and manufacturing organisations (CDMOs), analysing the position of companies manufacturing monoclonal antibody drugs (mAbs). Yoshiura et al. Yoshiura et al. Yoshiura et al. Yoshiura et al.